Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Huons CoXKRX:243070 +3.37%89 EBITDA Margin % is 5.57% as of Mar. 2026, which is 63% below its 10-year median of 14.89. GuruFocus rates XKRX:243070 with a GF Score™ of 89/100 and a GF Value™ of ₩32,635.94 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Huons Co ranks worse than 52.13% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Huons Co's EBITDA for the
three
months ended in Mar. 2026 was ₩7,900 Mil. Huons Co's Revenue for the
three
months ended in Mar. 2026 was ₩141,871 Mil. Therefore, Huons Co's EBITDA margin for the quarter that ended in Mar. 2026 was 5.57%.
Huons Co (XKRX:243070) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Huons Co EBITDA Margin % Related Terms
Huons Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Huons Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Huons Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Huons Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Huons Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Huons Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Huons Co (XKRX:243070) has a EBITDA Margin % of 5.57% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Huons Co and its competitors. This is 63% below median its historical median of 14.89. Over the past decade, Huons Co's EBITDA Margin % has ranged from 10.54 to 20.94. According to the industry distribution chart, Huons Co ranks #501 out of 961 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is Huons Co's EBITDA Margin % too high?
Huons Co's current EBITDA Margin % of 5.57% is 63% below median its 10-year median of 14.89. Over the past 10 years, this metric has ranged from a low of 10.54 to a high of 20.94. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Huons Co's value of 5.57% is 55.2% below this industry median. Based on the distribution chart, Huons Co ranks #501 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Huons Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Huons Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Huons Co ranks #501 out of 961 companies for EBITDA Margin %. This places Huons Co in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Huons Co's value of 5.57% is 55.2% below this benchmark. Historically, Huons Co's own EBITDA Margin % has ranged from 10.54 to 20.94 over the past decade. While the company's 10-year median is 14.89 vs. the industry median of 12.44, Huons Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Huons Co's current EBITDA Margin % of 5.57% is 55.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Huons Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Huons Co's current EBITDA Margin % is 5.57%, which is 63% below median its own 10-year median of 14.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Huons Co stock overvalued right now?
Based on GuruFocus' analysis, Huons Co (XKRX:243070) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩32,635.94, compared to a current price of ₩24,550.00 — trading 24.8% below its estimated fair value. The current EBITDA Margin % is 5.57%, which is 63% below median its 10-year median of 14.89 and 55.2% below the Drug Manufacturers industry median of 12.44. Huons Co's overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Huons Co (XKRX:243070), the current EBITDA Margin % is 5.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Huons Co (XKRX:243070) Overvalued in 2026?
Based on GuruFocus' analysis, Huons Co stock appears to be undervalued.
The current stock price of ₩24,550.00 is trading 24.8% below its estimated GF Value™ of ₩32,635.94.
GuruFocus considers Huons Co to be Modestly Undervalued.
Key valuation signals for XKRX:243070:
EBITDA Margin %: 5.57% (63% below median its 10-year median of 14.89)
GF Value™: ₩32,635.94 vs. price of ₩24,550.00 (24.8% below fair value)
Industry Position: 55.2% below the Drug Manufacturers median (#501 of 961)
No single metric tells the full story. See the XKRX:243070 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Huons Co Ltd is a Korean company. It is engaged in the manufacture and distribution of pharmaceutical products. The company produces pharmaceutical products including parenteral injections such as lidocaines, merit C injections; tablets such as phentermine, diet pills, and capsules such as Daisen and Fuxetine and other ethical and over-the-counter drugs. It also produces ampoules, vials, cartridges, and caps for use of medicals, foods, and cosmetics.
89GF Score
Get the complete analysis for XKRX:243070
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:243070 has been successfully added to your 
